1000336-41-3Relevant academic research and scientific papers
Selective Kv1.5 blockers: Development of (R)-1-(methylsulfonylamino)-3-[2- (4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a potential treatment for atrial arrhythmia
Blass, Benjamin E.,Fensome, Andrew,Trybulski, Eugene,Magolda, Ronald,Gardell, Stephen J.,Liu, Kun,Samuel, Manoj,Feingold, Irene,Huselton, Christine,Jackson, Chris M.,Djandjighian, Laurent,Ho, Douglas,Hennan, James,Janusz, John M.
supporting information; experimental part, p. 6531 - 6534 (2010/04/03)
Atrial fibrillation is the most prevalent form of cardiac arrhythmia. Current treatments extend the atrial effective refractory period by nonselective blockade of cardiac ion channels. An alternative approach selectively targeting the Kv1.5 ion channel of
